Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in ...
Metabolism has always been a crucial pillar in cancer treatment, but clinical considerations have been limited to general diet and nutrition advice, minimizing the potential therapeutic impact of ...
GLP-1 receptor agonists (GLP-1Ras) significantly outperformed Aspirin (acetylsalicylic acid) in reducing the risk of colorectal cancer, regardless of a patient’s weight or diabetes status, according ...
HOUSTON -- Two-thirds of patients with PI3K-mutant brain metastases responded to the maximum tolerated dose (MTD) of the small-molecule inhibitor paxalisib plus radiation therapy (RT), a small phase I ...
A common over-the-counter medication could significantly reduce the risk of colorectal cancer coming back. In a Swedish study, a low dose of aspirin was shown to slash recurrence in half for patients ...
Identifying Oncology Clinical Trial Candidates Using Artificial Intelligence Predictions of Treatment Change: A Pilot Implementation Study Pretreatment tumor was evaluated from operable TNBC patients ...
The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and fulvestrant to treat locally advanced, PIK3CA ...
A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback